本文選題：復(fù)方芪術(shù)湯　切入點(diǎn)：高效抗反轉(zhuǎn)錄病毒　出處：《復(fù)旦大學(xué)》2014年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：研究目的：研究中藥復(fù)方芪術(shù)湯聯(lián)合高效聯(lián)合抗反轉(zhuǎn)錄病毒治療(HAART)對(duì)脾虛濕盛型艾滋病患者的臨床療效及安全性。研究方法：收集符合抗病毒標(biāo)準(zhǔn)的脾虛濕盛型艾滋病患者共90例,將其隨機(jī)分為三組：第一組單用HAART組(30例)；第二組用唐草片聯(lián)合HAART組(30例)：在HAART基礎(chǔ)上,予唐草片每日三次,一次8�？诜�；第三組用復(fù)方芪術(shù)湯聯(lián)合HAART組(30例)：在HAART基礎(chǔ)上,予復(fù)方芪術(shù)湯煎劑每日兩次,一次300m1,飯后口服,或復(fù)方芪術(shù)湯顆粒,一天兩次,一次一包沖服。每組均治療6個(gè)月,觀察3個(gè)月及6個(gè)月時(shí)三組患者中醫(yī)證候積分變化、CD4+T淋巴細(xì)胞計(jì)數(shù)、體重變化及治療過(guò)程中血常規(guī)、肝腎功能等安全指標(biāo)的異常率。研究結(jié)果：1.中醫(yī)癥狀體征積分：唐草片聯(lián)合HAART組、復(fù)方芪術(shù)湯聯(lián)合HAART組治療3個(gè)月、6個(gè)月后積分較治療前下降,差異均有統(tǒng)計(jì)學(xué)意義(P0.05或P0.01)；唐草片聯(lián)合HAART組、復(fù)方芪術(shù)聯(lián)合HAART組治療3個(gè)月、6個(gè)月后對(duì)比單用HARRT組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05或P0.01)。其中,唐草片聯(lián)合HAART組與復(fù)方芪術(shù)聯(lián)合HAART湯組兩組之間治療3、6個(gè)月后差異均無(wú)統(tǒng)計(jì)學(xué)意義。2.中醫(yī)證候療效：唐草片聯(lián)合HAART組、復(fù)方芪術(shù)湯聯(lián)合HAART組治療后3個(gè)月較單用HAART組總有效率高,其差異有統(tǒng)計(jì)學(xué)意義(P0.01)。唐草片聯(lián)合HAART組、復(fù)方芪術(shù)湯聯(lián)合HAART組治療后6個(gè)月較單用HAART組總有效率高,其差異有統(tǒng)計(jì)學(xué)意義(P0.01)。其中復(fù)方芪術(shù)湯聯(lián)合HAART組和唐草片聯(lián)合HAART組無(wú)明顯差別。3、三組治療后CD4+T淋巴細(xì)胞計(jì)數(shù)變化：相比治療前,三組治療3、6個(gè)月后CD4+T淋巴細(xì)胞計(jì)數(shù)差異均有統(tǒng)計(jì)學(xué)意義(P值0.05或P值0.01)；治療6月后,唐草片聯(lián)合HAART組、復(fù)方芪術(shù)湯聯(lián)合HAART組對(duì)比HAART CD4+T淋巴細(xì)胞計(jì)數(shù)差異均有統(tǒng)計(jì)學(xué)意義(P值0.05)。其中復(fù)方芪術(shù)湯聯(lián)合HAART組和唐草片聯(lián)合HAART組無(wú)明顯差別。4、體重變化：?jiǎn)斡肏AART組治療3月、6月后體重下降,對(duì)比治療前差異均有統(tǒng)計(jì)學(xué)意義(P值0.05或P值0.01)：治療6個(gè)月較治療3個(gè)月后進(jìn)一步下降(P0.01)。5、安全性指標(biāo)：各組患者治療后一般體格檢查、尿常規(guī)、糞常規(guī)、腎功能、心電圖等檢測(cè)均無(wú)明顯異常變化。各組之間治療期間發(fā)生WBC、Hb、PLT異常率差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。各組之間治療期間發(fā)生ALT、AST、TB異常率差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論：復(fù)方芪術(shù)湯聯(lián)合HAART治療脾虛濕盛型艾滋病在改善中醫(yī)癥狀體征、提高CD4+T淋巴細(xì)胞計(jì)數(shù)、增加體重等方面顯示出較好的臨床療效；較單用HAART效果明顯；其臨床治療效果與唐草片聯(lián)合HAART相當(dāng)。復(fù)方芪術(shù)湯聯(lián)合HAART治療艾滋病臨床安全性較好,無(wú)明顯不良反應(yīng)。
[Abstract]:Objective: to study the clinical efficacy and safety of traditional Chinese medicine compound Qizu decoction combined with highly effective antiretrovirus therapy in the treatment of patients with spleen deficiency and dampness. Methods: to collect spleen deficiency dampness abundant type according to antiviral standard. There were 90 AIDS patients, They were randomly divided into three groups: the first group was treated with HAART alone, the second group was treated with Tangcao tablet combined with HAART group (30 cases): on the basis of HAART, 8 tablets of Tangcao tablet were given three times a day, and the third group was treated with compound Qizhutang combined with HAART group (30 cases) on the basis of HAART. Take compound Qizhutang decoction twice a day, 300ml once a day, take orally after meals, or compound Qizhutang granules, twice a day, one pack at a time. Each group is treated for 6 months. The changes of TCM syndromes integral and CD4 T lymphocyte count, weight change and blood routine during treatment were observed in three groups at 3 and 6 months. The abnormal rate of safety indexes such as liver and kidney function. Results: 1. Score of symptoms and signs of traditional Chinese medicine: Tangcao tablet combined with HAART group, compound Qizu decoction combined with HAART group for 3 months, the score after 6 months was lower than that before treatment. The differences were statistically significant (P 0.05 or P 0.01), Tangcao tablet combined with HAART group, compound astragalus injection combined with HAART group for 3 months, and after 6 months compared with HARRT group, the differences were statistically significant (P0.05 or P0.01). Tangcao tablet combined with HAART group and compound Qizu combined with HAART decoction group, there was no significant difference between the two groups after 6 months. 2.Therapeutic effect of TCM syndrome: Tangcao tablet combined with HAART group; Three months after treatment, the total effective rate of compound Qizu decoction combined with HAART group was higher than that of HAART group, and the difference was statistically significant (P 0.01). The total effective rate of Tangcao tablet combined with HAART group and Fufang Qizhutang combined HAART group was higher than that of HAART group at 6 months after treatment. The difference was statistically significant (P 0.01). There was no significant difference between compound Qizhutang combined with HAART group and Tangcao tablet combined with HAART group. The changes of CD4 T lymphocyte count in the three groups after treatment were as follows: compared with before treatment, there was no significant difference between the three groups. There were significant differences in CD4 T lymphocyte count between the three groups after 3 and 6 months of treatment (P 0. 05 or P 0. 01), and after June, Tangcao tablet combined with HAART group. There was significant difference in T lymphocyte count of HAART CD4 between the two groups (P < 0.05). There was no significant difference between the two groups. There was no significant difference between the two groups. 4. Weight change: HAART group was treated on March. Weight loss since June, The differences before treatment were statistically significant (P 0.05 or P 0.01): after 6 months of treatment compared with 3 months after treatment, there was a further decrease in P 0.01g. 5. Safety index: general physical examination, urine routine, routine fecal routine, renal function after treatment in each group, safety index: general physical examination after treatment, routine urine routine, routine fecal routine, renal function, and so on. There were no obvious abnormal changes in electrocardiogram and so on. There was no significant difference in the abnormal rate of WBCn HbP PLT between the groups during treatment. There was no significant difference in the abnormal rate of alt ASTT TB in all groups during the treatment period. Conclusion: there is no significant difference in the abnormal rate of alt ASTTTB in the treatment period. Conclusion: compound astragalus surgery has no significant difference in the abnormal rate. Decoction combined with HAART in the treatment of spleen deficiency and dampness of AIDS in improving the symptoms and signs of traditional Chinese medicine, Increasing CD4 T lymphocyte count and increasing body weight showed better clinical efficacy than that of HAART alone, and its clinical efficacy was similar to that of Tangcao tablet combined with HAART. Compound Qizu decoction combined with HAART had better clinical safety in the treatment of AIDS. There was no obvious adverse reaction.
【學(xué)位授予單位】：復(fù)旦大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類(lèi)號(hào)】：R512.91

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 陳春霞,趙大明,張秀軍,林志彬;羧甲基茯苓多糖的抗腫瘤實(shí)驗(yàn)[J];福建中醫(yī)藥;2002年03期

2 陳曉蓉;楊宗國(guó);沈芳;王江蓉;盧洪洲;巫善明;;復(fù)方芪術(shù)湯對(duì)脾虛型艾滋病患者中醫(yī)證候的療效及外周血CD4 T淋巴細(xì)胞的影響[J];上海中醫(yī)藥大學(xué)學(xué)報(bào);2010年06期

3 金鑫;;銀杏葉提取物藥理研究進(jìn)展[J];天津藥學(xué);2012年02期

4 賈新亭;付芳玉;郭震;索芳玉;李?lèi)?ài)軍;周青山;;中藥治療艾滋病腹瀉探討[J];亞太傳統(tǒng)醫(yī)藥;2007年07期

5 蘇誠(chéng)煉;;中醫(yī)試治艾滋病30例臨床報(bào)告[J];中醫(yī)藥學(xué)報(bào);1991年02期

6 曾凡力;程悅;陳建萍;符影;王巧利;楊得坡;陳振平;向陽(yáng)飛;王一飛;王冬梅;;雞血藤醇提物體外抗病毒活性研究[J];中藥新藥與臨床藥理;2011年01期

7 田明;張偉;倪量;徐立然;張明利;郭長(zhǎng)河;譚行華;岑玉文;黃葵;孫麗君;高輝;陳建華;劉景院;周玉玲;萬(wàn)剛;華文浩;王慧珠;王融冰;王玉光;;中醫(yī)藥治療艾滋病相關(guān)性慢性腹瀉患者311例臨床研究[J];中醫(yī)雜志;2012年12期

，

本文編號(hào)：1588843